Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts

Bone

Volumn 20, Issue 5, 1997, Pages 399-404

  Murakami, H ^a,b   Takahashi, N ^a   Tanaka, S ^a,c   Nakamura, I ^a,c   Udagawa, N ^a   Nakajo, S ^a   Nakaya, K ^a   Abe, M ^b   Yuda, Y ^b   Konno, F ^b   Barbier, A ^d   Suda, Tatsuo ^a  

^a SHOWA UNIVERSITY   (Japan)

^b MEIJI SEIKA KAISHA LTD   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d SANOFI   (France)

Author keywords

Bisphosphonates; F actin ring; Osteoclast; Protein tyrosine phosphatase; Tyrosine phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; F ACTIN; PHOSPHOTYROSINE; PROTEIN TYROSINE PHOSPHATASE; TILUDRONIC ACID;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL LYSATE; CYTOSKELETON; ENZYME INHIBITION; MALE; MOUSE; MULTINUCLEAR CELL; NEWBORN; NONHUMAN; OSTEOCLAST;

ACTINS; ANIMALS; BONE RESORPTION; CATTLE; CELLS, CULTURED; CYTOSKELETON; DIPHOSPHONATES; ENZYME INHIBITORS; MICE; OSTEOCLASTS; PHOSPHOTYROSINE; PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL TRANSDUCTION;

EID: 0030918039     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(97)00025-2     Document Type: Article

References (28)

1. Akatsu, T., Tamura, T., Takahashi, N., Udagawa, N., Tanaka, S., Sasaki, T., Yamaguchi, A., Nagata, N., and Suda, T. Preparation and characterization of a mouse osteoclast-like multinucleated cell population. J Bone Miner Res 7:1297-1306; 1992.
2. Amin, D., Cornell, S. A., Gustafson, S. K., Needl, S. J., Ullrich, J. W., Bilder, G. E., and Perrone, M. H. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663; 1992.
3. Atack, J. R., Cook, S. M., Watt, A. P., Fletcher, S. R., and Ragan, C. I. In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J Neurochem 60:652-658; 1993.
4. Aubin, J. E. Osteoclast adhesion and resorption: The role of podosomes. J Bone Miner Res 7:365-368; 1992.
5. Baron, R. Molecular mechanisms of bone resorption by the osteoclast. Anat Rec 224:317-324; 1989.
6. Fleisch, H. Bisphosphonates: Mechanisms of action and clinical use. In: Mundy, G. R. and Martin, T. J., Eds. Physiology of bone. Berlin: Springer; 1993; 377-418.
7. Fleisch, H., Russell, R. G. G., and Francis, M. D. Diphosphonates inhibit hydroxyaptite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-1264; 1969.
8. Kole, H. K., Akamatsu, M., Ye, B., Yan, X., Barford, D., Roller, P. P., and Burke, T. R., Jr. Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, L-O-malonyltyrosine. Biochem Biophys Res Commun 209:817-822; 1995.
9. 2, and dibutyryl cyclic adenosine 3′,5′-monophosphate disperse the specific micro-filament structure in resorbing osteoclasts. J Histochem Cytochem 38:1487-1493; 1990.
10. Lakkakorpi, P. T. and Väänänen, H. K. Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro. J Bone Miner Res 6:817-826; 1991.
11. Lowe, C., Yoneda, T., Boyce, B. F., Chen, H., Mundy, G. R., and Soriano, P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 90:4485-4489; 1993.
12. Murakami, H., Takahashi, N., Sasaki, T., Udagawa, N., Tanaka, S., Nakamura, I., Zhang, D., Barbier, A., and Suda, T. A possible mechanism of specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17:137-144; 1995.
13. Nakajo, S., Omata, K., Aiuchi, T., Shibayama, T., Okahashi, I., Ochiai, H., Nakai, Y., Nakaya, K., and Nakamura, Y. Purification and characterization of a novel brain-specific 14-kDa protein. J Neurochem 55:2031-2038; 1990.
14. Nakamura, I., Takahashi, N., Sasaki, T., Jimi, E., Kurokawa, T., and Suda, T. Chemical and physical properties of the extracellular matrix are required for the actin ring formation in osteoclasts. J Bone Miner Res 11:1873-1879; 1996.
15. Nakamura, I., Takahashi, N., Sasaki, T., Tanaka, S., Udagawa, N., Murakami, H., Kimura, K., Kabuyama, K., Kurokawa, T., Suda, T., and Fukui, Y. Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption. FEBS Lett 361:79-84; 1995.
16. Nishibe, S., Wahl, M. I., Rhee, S. G., and Carpenter, G. Tyrosine phosphorylation of phospholipase C-II in vitro by the epidermal growth factor receptor. J Biol Chem 264:10335-10338; 1989.
17. Schmidt, A., Rutledge, S. J., Endo, N., Opas, E. E., Tanaka, H., Wesolowski, G., Leu, C. T., Huang, Z., Ramachandaran, C., Rodan, S. B., and Rodan, G. A. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate. Proc Natl Acad Sci USA 93:3068-3073; 1996.
18. Soriano, P., Montgomery, C., Geske, R., and Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702; 1991.
19. Suda, T., Takahashi, N., and Martin, T. J. Modulation of osteoclast differentiation. Endocrine Rev 13:66-80; 1992.
20. Sun, H. and Tonks, N. K. The coordinated action of protein tyrosine phosphatases and kinases in cell signaling. Trends Biochem Sci 19:480-485; 1994.
21. FAK, in osteoclastic bone resorption. J Cell Biochem 58:424-435; 1995.
22. c-src, preferentially on raffled border membranes. FEBS Lett 313:85-89; 1992.
23. Teti, A., Marchisio, P. C., and Zambonin Zallone, A. Clear zone in osteoclast function: Role of podosomes in regulation of bone-resorbing activity. Am J Physiol 261:C1-C7; 1991.
24. Tezuka, K., Sato, T., Kamioka, H., Nijweide, P. J., Tanaka, K., Tatsuo, T., Ohta, M., Kurihara, N., Hakeda, Y., and Kumegawa, M. Identification of osteopontin in isolated rabbit osteoclasts. Biochem Biophys Res Commun 186:911-917; 1992.
25. Väänänen, H. K. and Horton, M. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 108:2729-2732; 1995.
26. Wesolowski, G., Duong, L. T., Lakkakorpi, P. T., Nagy, R. M., Tezuka, K., Tanaka, H., Rodan, G. A., and Rodan, S. B. Isolation and characterization of highly enriched, prefusion mouse osteoclastic cells. Exp Cell Res 219:679-686; 1995.
27. c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. J Clin Invest 91:2791-2795; 1993.
28. Zhang, D., Udagawa, N., Nakamura, I., Murakami, H., Saito, S., Yamasaki, K., Shibasaki, Y., Morii, N., Narumiya, S., Takahashi, N., and Suda, T. The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 108:2285-2292; 1995.